UNIVERSITY OF LEEDS

This is a repository copy of Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer.

White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/142576/

Version: Accepted Version

Article:

Ham-Karim, HA, Ebili, HO, Manger, K et al. (4 more authors) (2019) Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer. Molecular Diagnosis & Therapy, 23 (3). pp. 383-393. ISSN 1177-1062

https://doi.org/10.1007/s40291-019-00388-z

© Springer Nature Switzerland AG 2019. This is an author produced version of a paper published in Molecular Diagnosis & Therapy. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

Authors: Hersh A. Ham-Karim^{1, 2}, Henry Okuchukwu Ebili^{1, 3}, Kirsty Manger⁴, Wakkas Fadhil¹, Narmeen S. Ahmad^{5, 6}, Susan D. Richman⁷ and Mohammad Ilyas¹.

Title: Targeted next generation sequencing validates the use of diagnostic biopsies as a suitable alternative to resection material for mutation screening in colorectal cancer.

Affiliations: ¹Division of Pathology, University of Nottingham, Queen's Medical Centre, UK. ²Department of Medical Laboratory Sciences, College of Health Sciences, Komar University of Science and Technology, Chaq-Chaq-Qualaraisi, Sulaimani City, Iraq. ³Department of Morbid Anatomy and Histopathology, Olabisi Onabanjo University, Agolwoye, Nigeria. ⁴Centre for Medical Genetics, Nottingham University Hospitals NHS Trust, City Hospital Campus, UK. ⁵Clinical Oncology, University of Nottingham, City Hospital Campus, UK. ⁶Kurdistan Institution for Strategic Studies and Scientific Research, Qirga, Sulaimani, KRG, Iraqi. ⁷Department of Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, Wellcome Trust Brenner Building, St James University Hospital, Leeds, UK

Corresponding author: Dr Henry O. Ebili, University of Nottingham, School of Medicine, Division of Pathology, Queen's Medical Centre, Nottingham, NG7 2UH. Henry.Ebili@nottingham.ac.uk

Key points:

- · The findings from this study have lent credence to the growing notion that diagnostic biopsies are very similar to resection samples at the molecular level.
- As such diagnostic biopsies can be used for molecular testing in place of resection samples.
- This creates an opportunity for neoadjuvant therapy and enhances personalised medicine.

+

ABSTRACT

Background

Mutation testing in the context of neoadjuvant therapy mustbe performed on biopsy samples. Given the issue of tumour heterogeneity, this raises the question of whether the biopsies are representative of the whole tumour. Here we have compared the mutation profiles of colorectal biopsies with their matched resection specimens.

Methods

We performed next generation sequencing (NGS) analysis on 25 paired formalin-fixed, paraffin-embedded (FFPE) colorectal cancer (CRC) biopsy and primary resection samples. DNA was extracted and analysed using the Trusight tumour kit, allowing the interrogation of 26 cancer driver genes. Samples were run on an Illumina MiSeq. Mutations were validated using quick-multiplex-consensus (QMC)-PCR in conjunction with High Resolution Melting (HRM). The paired biopsy and resection tumour samples were assessed for presence or absence of mutations, mutant allele frequency ratios, and allelic imbalance status.

Results

A total of 81 mutations were detected, in 10 of the 26 genes in the Trusight Kit. Two of the 25 paired cases were wild-type across all genes. The mutational profiles, allelic imbalance status, and mutant allele frequency ratios of the paired biopsy and resection samples were highly concordant (88.75 – 98.85%), with all but three (3.7%) of the mutations identified in the resection specimens, also being present in the biopsy specimens. All 81 mutations were confirmed by QMC-PCR and HRM analysis, although four low-level mutations required a COLD-PCR protocol to enrich for the mutant alleles.

Conclusions

Diagnostic biopsies are adequate and reliable materials for molecular testing by NGS. The use of biopsies for molecular screening will enhance targeted neoadjuvant therapy.

1 INTRODUCTION

Colorectal cancer (CRC) is the third most common malignancy, and a 5th leading cause of cancer deaths worldwide [1].In the United Kingdom, CRC is the 4th most common cancer and the 5th most common cause of cancer deaths, accounting for 10% of all cancer deaths [2].Recent advances in genome sequencing technologies have enabled greater understanding of the molecular mechanisms of tumourigenesis and aided the identification of clinically relevant biomarkers for diagnosis and personalized therapeutics [3, 4].The discovery of predictive biomarkers and the development of targeted therapies are currently used in guiding personalised therapy. One example of a 'stratified medicine' approach in CRC is tumour assessment for the presence of mutations in the *KRAS or NRAS* genes, which predicts a lack of response to EGFR-targeted antibodies such as panitumumab or cetuximab [4, 5]. Constitutive activation of either *KRAS* or *NRAS* results in excess signalling through the RAS/ Mitogen-activated protein kinase pathway which cannot be negated by the anti-EGFR monoclonal antibody therapies.

Currently, tumour materials from both biopsy and resection specimens are recommended for use in the predictive testing of adjuvant targeted therapy response in stage II-III CRC, in the absence of metastatic or recurrent tumour [6]. However, the use of neoadjuvant therapy in patients with CRC is likely to increase and at present many predictive biomarkers for neoadjuvant therapy prediction are under study [7, 8]. Whilst neoadjuvant therapy is available for patients with rectal tumours, a clinical trial of neoadjuvant chemotherapy for locally advanced colonic cancer was recently started in the UK and elsewhere [7-10]. In the setting of neoadjuvant therapy, biopsy specimens may be the only available specimens to test *KRAS*, *NRAS* and *BRAF* mutations as recommended for the current standard-of-care of metastatic colorectal cancers. If the studies on the use of neoadjuvant therapy show desirable outcomes, then the diagnostic biopsy specimens may become the only material available for predictive testing in the neoadjuvant settings [11]. CRC develops as a consequence of waves of clonal expansion, resulting from mutations called 'driver mutations' giving a selective advantage [12]. These driver mutations, which are responsible for early clonal sweeps

| Page

through the adenoma-carcinoma sequence, should therefore be predominantly present in most of the tumour cells and consequently should be present in any biopsy samples of an individual tumour.

To confirm whether this is indeed the case and whether diagnostic biopsy specimens are appropriate for predictive testing, we have carried out mutation screening of 25 paired diagnostic biopsies (Bx) and their matched resection specimens (Rx). A sensitive next generation sequencing (NGS) approach was used to assess the presence of mutations in a panel of 26 genes involved with solid tumours.

2 MATERIALS AND METHODS

2.1 Clinical samples

FFPE sporadic CRC tumour blocks were retrieved from the archives of the Nottingham University Hospitals Department of Histopathology. All patients had undergone surgery between 2004 and 2005. Cases were selected based on the availability of clinicopathological data and the presence of at least 50% tumour cells in both Bx and Rx. DNA was extracted using the Qiagen mini Kit from 25 cases of paired biopsy samples and resection specimens as previously described [11]. Baseline characteristics are reported in Online Resource table 1.

2.2 Next generation sequencing (NGS) library preparation

Mutation profiles were determined using the TruSight tumour kit (Illumina, USA) and samples run on an Illumina MiSeq (Illumina, USA). The TruSight tumour kit offers deep coverage of 26 genes across 175 amplicons (a minimum 1000X coverage, an average of 7000X coverage). Each sample underwent a quality control (QC) step to test for template integrity according to the kit manufacturer's instructions. PCR-based library preparation was carried out in accordance with the manufacturers' instructions. The libraries were cleaned up, then diluted to a final concentration of 4nM before pooling. Captured libraries were amplified and sequenced as paired-end reads on a MiSeq flow cell, with a total of 12 samples being run on each cell.

2.3 NGS data analysis

Base calling, quality score assignment and trimming of low quality reads (using a minimum Q-score of 20) were performed on the MiSeq reporter v2.1 suite. The generated FASTQ files were aligned to the reference genome (hg19). Following alignment, the sequence variants (single nucleotide variants (SNVs) and insertions or deletions (indels)) detected in the generated BAM files were assembled into a vcf format. The VariantstudioTM v2.1analyser was used to perform variant filtering and annotation. The following criteria were used to define sequence variants -germline and somatic- and rule out mutation artefacts: (1) average wild-type read depth of >500X per

pool, (Online Resource table 2) (2) occurrence in both forward and reverse sequencing pools, (3) >3% mutant allele frequency in the merged vcf files. The dbSNP reference was used to separate germline from somatic sequence variants.

To assess the intra-assay variability of the NGS platform, we performed short-term precision assay by testing one sample in 8 replicates in the same run. The inter-assay variability was assessed with the long-term precision assay by testing the same sample in 3 different runs. For each precision assay we determined the coefficient of variation (CV).

2.4 QMC-PCR and high resolution melting (HRM) analysis

As a means of validating the mutations detected by NGS, the samples were also analysed using the quick-multiplex-consensus (QMC)-PCR in conjunction with a high resolution melting (HRM) protocol as previously described [13]. Derivative and difference plots were generated to separate mutant from wild-type samples, as described elsewhere [13, 14].

2.5 Molecular similarity between Bx and Rx

To verify if the Bx were representative of the Rx at the molecular level, we investigated the similarities between the diagnostic biopsy and resection sample pairs by using three indices which have shown relevance in the clinical and biological behaviours of cancers: *somatic mutation profiles, mutant allele frequency ratios* (MAFRs), and *allelic imbalance* (AI) status – within the limitations of the TruSight tumour targeted panel. Since each of the pairs of Bx and Rx are from the same tumours, they must be similar at the molecular level, i.e. not only must their mutation profiles match, but their mutant frequency ratios and allelic imbalance scores must be in the same ranges.

A crude percentage concordance was used to calculate the extent to which the diagnostic biopsies match the somatic mutation profiles, mutant allele frequency ratios, and allelic imbalance status of their corresponding resection samples, whilst the kappa test (Quick calcs (<u>www.graphpad.com/quickcalcs/kappa2/</u>) and Kappa

(www.vassarstats.net/kappa.html)) was used to validate the crude percentage

concordance test results [15, 16]. Mean difference in MAF between Rx and Bx was calculated using the online GraphPad software (<u>www.graphpad.com</u>).

2.6 Performance evaluation of NGS-based somatic mutation profiling of Bx

As the 26-gene TruSight Tumour Somatic Mutation panel has translated into clinical use (<u>www.clinicallabs.com.au/doctor/specialists-services/haematology-oncology/</u>) we tested the following performance indices of the NGS-based somatic mutation profiling of Bx: sensitivity, specificity, negative and positive predictive values (NPV and PPV). See Online Resource table 3. The performance indices as used here are merely to show the similarities between Rx and Bx at the molecular level and not strictly as diagnostic tests of accuracy.

3 RESULTS

The NGS short-term precision assay showed a mean coefficient of variation of 12.3% (range 8.6% - 15.3%) for sequencing depth and 2.5% (range 1.6%-4.4%) for mutant allele frequency (MAF). The long-term precision assay showed a mean CV of 10.6% (range 3.2% - 15.1%) for sequencing depth and 2.2% (range 0.01%-6.1%) for MAF. The mean sequencing depth obtained was 14803 (range 1366 - 44577), whilst the limit of detection of the mutant alleles was 3%.

3.1 Paired biopsy and resection mutation profiles

A total of 78 and 81 somatic mutations were found in the Bx and Rx samples, respectively. Only 2/25 (8%) tumour pairs displayed a wild-type genotype across all 26 genes included in the panel. The distribution of mutations detected in the 25 paired samples, are shown in table 1 and Online Resource table 2. In sample 9, the GNAS c.2531G>A mutation was not detected in the Bx sample. In sample 13, only the Rx contained the GNAS c.2543C>T mutation. In sample 20, both the Bx and Rx contained the TP53 c.524G>A mutation, but only the Rx contained the TP53 c.23C>T mutation. (32%) of Only 8/25 tumours contained the full complement of the APC/KRAS(BRAF)/TP53 mutations of the Fearon and Vogelstein pathway. Furthermore, the frequency of APC mutations (56%) was lower than that of TP53 mutations (68%) and this is consistent with published data. Although overall, the MAF was 1.003-fold lower in resection specimens than biopsies, but on a mutation-bymutation basis, the MAF showed no consistent pattern of abundance between the Rx and Bx samples. Moreover, there was no significant difference in the mean MAF between Rx and Bx samples (difference in mean MAF=0.753, P=0.748). Furthermore, the three mutations not detected in Bx were present in the matched Rx at frequencies of <4%. There were no mutations in the Bx that were not seen in the Rx (table 1). In all, only 10 of the 26 genes in the TruSight panel were found to be mutated in the Rx and Bx samples.

3.2 Validation of mutations

QMC-PCR in conjunction with HRM was used to validate the mutations identified, and initially 77/81 (95.1%) of the mutations were successfully validated (Online Resource figure 1). The remaining four mutations (4.9%) were only validated by HRM following minor allele enrichment by the modified COLD-PCR protocol (Online Resource figure 2). These four "false negatives" samples were subsequently reassigned as "true positives".

3.3 Allelic Imbalance

Quantification of heterozygous SNPs was used to indicate allelic loss if there is deviation from 50% (outside the range seen in natural assay variation). Based on the maximum CV of 4.4% obtained from the short-term precision assay, and the calculated mean MAF of normal SNPs (49.9%), the normal range for SNPs in the tumour samples was calculated to be 43.3-56.5% for all SNPs. Based on this, allelic imbalance was found in Rx and matched Bx samples as shown in table 2.

3.4 Concordance in molecular alteration status between Rx and Bx pairs

To determine the similarity between Bx and their corresponding Rx at the molecular level we determined the concordance in their somatic mutation profiles. A simple 'mutation-present-or-absent' count was used to determine the mutation status match between Bx and Rx. Only the 10 mutated genes were used in this analysis which included all 50 cases (25 Bx and 25 Rx). A total of 261 Rx-Bx mutation pairs were counted (Online Resource figure 3). Of these, Bx and Rx showed concordance in 258 pairs (78 mutations and 180 no-mutations) and discordance in 3 pair (all Rx: mutations/ Bx: no-mutations). There was no Rx: no-mutation/ Bx: mutation pair. Also, all the mutations that matched were of the same bases in the same gene loci in Rx and Bx (tables 1 and 3). A crude percentage concordance of 98.85% (258/261) was calculated for the mutation status of Rx and Bx. The event indices were input into the online kappa calculators, QuickCalcs and Kappa. The result showed a Kappa of 0.971 [standard error (SE) of 0.016 and 95% confidence interval (CI) of 0.942-1.000] which is classified as

'almost perfect' agreement (see reference 28) or 'very good' agreement (see figure 1a). Furthermore, the level of agreement between Bx and Rx in allelic imbalance status was investigated. All 25 sample pairs with 80 informative SNP loci, cumulatively, were included in the analysis. Allelic imbalance status was categorized into three classes: allelic imbalance with loss of wild-type allele (LWA, SNP % > 56.5%), allelic imbalance with loss of polymorphic allele (LPA, SNP % <43.3%) and nil allelic imbalance (NAI, SNP % within normal range of 43.3% and 56.5%). The Rx/Bx pairs were scored concordant when their SNP classes match, otherwise they were considered discordant. A total of 80 pairs were counted, comprising 51/80 NAI pairs, 7/80 LWA pairs and 13/80 LPA paired. Discordance was found between Rx and Bx in 10/80 events (Rx/Bx: NAI/LPA=3; NAI/LWA=2; LPA/NAI=2; LWA/NAI=2; LPA/LWA=0 and LWA/LPA=0) (see table 2). A crude percentage concordance of 88.75% (71/80) was calculated, giving a very good agreement between Bx and Rx for allelic imbalance status (figure 1b). Kappa test also showed a 0.76 concordance (SE of 0.076 and 95% CI between 0.612 and 0.908).

Moreover, the total MAFRs were compared between Rx and Bx. We reasoned that if Bx were truly representative of Rx's there should be some retention of the relative MAF ratios across the tumour body, despite the presence of clonal heterogeneity. A total of 20/25 sample pairs, including only Rx/Bx pairs with two or more mutations in at least one of the Rx/Bx pairs were included in this analysis. The MAFRs for both Rx and Bx were calculated relative to the MAF of the first gene loci MAF in each Rx sample on table 1. The Rx/Bx pair was considered concordant if both MAF ratios were either <1 or >1. If the MAF ratios for the Bx/Rx pair were <1 and >1, but were within 1+0.05, they were also considered concordant. Otherwise, they were taken as discordant. Also, samples in which one member of the pair was missing a corresponding mutation were considered discordant and were classed into the Bx<1/Rx>1 category as the Rx MAF ratios in all those cases were >1. A total of 58 mutation pairs were counted comprising 52 concordant observations between Rx and Bx (comprising 45 MAF ratio pairs <1, 6 MAF ratio pairs >1 and 1 MAF ratio pair =1+0.05) and 6 discordant observations (all Bx<1/Rx>1). There was zero Bx:>1/Rx:<1 MAF ratio pair. A crude percentage concordance rate of 89.6% was calculated for the total MAF ratios of Rx and Bx. Kappa

was 0.651(SE=0.128, 95% CI=0.400-0.901). Both tests again returned a 'good' to 'very good' agreement scores between the MAF ratios of Bx and Rx samples (figure 1c).

3.5 Performance evaluation of NGS-based somatic mutation profiling of Bx

We evaluated the use of Bx for mutation detection by NGS using established tests of performance (Online Resource table 3). Using the Rx as the 'gold standard' samples and taking each of the somatic mutations detected (or not detected) as individual observations the following parameters were derived for Bx samples: number of true positive tests (TP)= 78, true negative (TN) =180, false positive (FP) =0 and false negative (FN) =3.

The indices of performance obtained for Bx include sensitivity of 96.3% with a false negative rate (FNR) of 3.7%, specificity of 100% with a false positive rate (FPR) of 0%, positive predictive value (PPV, precision) value of 100%, negative predictive value (NPV) of 98.4%, accuracy of 98.85%, and a false discovery rate (FDR) of 0%, altogether indicating a high performance of Bx as suitable samples for molecular testing by NGS.

4 DISCUSSION

Recent advances towards personalised medicine are driven by the identification of targetable mutations. For example, treatment of non-small cell lung cancer patients with gefitinib is dependent upon *EGFR* mutation status [18]. Herceptin administration is only considered in a subset of breast and gastric cancer patients with *HER2* amplification [18, 19]. In CRC patients with advanced disease, mutation screening of *KRAS* and *NRAS* is required prospectively, if anti-EGFR monoclonal antibody therapies are being considered, as responses have only been seen in wild-type tumours [5, 20].

Where targeted neoadjuvant chemotherapy is being offered to patients, mutation screening must be carried out on the diagnostic biopsy specimen. Thus, the question arises as to whether a biopsy specimen, which represents a tiny proportion of the tumour, is adequately representative of the whole tumour and thus can be used in patient stratification. Previously, we and others showed that FFPE diagnostic biopsy tissues were adequate for testing microsatellite instability and other molecular alterations in colorectal cancer by low throughput methods such as HRM analysis, direct sequencing, pyrosequencing, and Therascreen Amplification Refractory Mutation System (ARMS)-Scorpion [11, 21]. Furthermore, other groups have demonstrated the feasibility and reliability of the use of small diagnostic biopsies for molecular testing by NGS [22-25]. In this study, despite the use of low quality DNA template derived from FFPE tissue, we obtained a mean sequencing depth of 14803 (range 1366 - 44577) and the limit of detection for the mutant alleles was 3%. There was good short-term and long-term precision, and all 81 somatic mutations detected using the TruSight panel were also validated by QMC-PCR and HRM. Validation of low level mutations required COLD-PCR to further enrich the mutant allele population.

In our sample set, the frequency of detected gene mutations was within the range of previously published literature [26, 27]. The most frequent mutations were in *TP53* whilst *APC* mutation was found in 56% of tumours. The sensitivity of targeted NGS analysis, allowed the detection, in the biopsy samples, of all but three of the 81 mutations detected in the paired resection samples. There was no significant difference in the mean MAF between Rx and Bx samples.

More importantly, we compared the degree of similarity between the Rx and Bx pairs at the molecular level using well established statistical tests and markers which have been shown to have biological and clinical importance [5, 17, 28-33]. The presenceor-absence-of-mutation-type and the allelic imbalance status tests showed very good concordance between the Rx and the Bx samples, an indication that the latter were adequately representative of the former. Furthermore, we applied the mutant allele frequencies ratios to test the degree of similarity between the two biopsy types and found a 'good' to 'very good' concordance between them. Whilst somatic mutation profiles and allelic imbalance status have established biological, prognostic and predictive utilities, MAF is currently under active clinical research for use as a marker for the estimation of tumour heterogeneity and prediction of cancer survival, targeted therapy response and the risks and foci of tumour metastases [29-33].

Furthermore, the Bx samples showed relatively high indices of performance as potential clinical test materials for somatic mutation detection by NGS, an indication that Bx is an adequate material for molecular testing for neoadjuvant therapy.

Although, our data indicate that biopsy specimens represent a feasible material for molecular testing, but to increase the probability of sampling of the dominant clone, some factors should be considered when interpreting data from tumour biopsy specimens. For example, from where was the tissue taken? The centre, or, invasive edge of the tumour? A study performed by Baldus et al [34] demonstrated a discrepancy in the frequency of mutations in KRAS, BRAF and PIK3CA by 8%, 1% and 5% respectively between the centre and the invasive edge of colorectal tumours [34], with one explanation of this discrepancy being that the invasive edges are probably more prone to stromal contamination than the central portions of the tumour. Another factor is related to tumour clonal heterogeneity [35]. Although we did find overall a strong agreement between Rx and Bx at the molecular level, we observed that a proportion of the Rx and Bx showed MAF discrepancies at some loci and that 3/81 Bx samples did not show the corresponding mutations which were observed in the Rx samples with MAFs <4%. Based on these factors we advocate that diagnostic biopsies with intent for molecular testing should sample multiple tumour areas to enhance mutation detection.

This study is limited by the number of SNPs that could be interrogated to allow a more comprehensive AI status analysis- the TruSight panel targets gene exons

which have lower SNP densities compared to introns. Another limitation of this study is the small sample size used for the evaluation of Bx as a suitable candidate for molecular testing by NGS. The use of a larger sample size is perhaps necessary to validate the use of diagnostic biopsy as an adequate biopsy for mutation detection on the NGS platform.

In conclusion, we have shown a high concordance between matched biopsy and resection samples within the mutation distributions of the genes in the TruSight tumour panel, suggesting that the use of diagnostic biopsies is not only feasible, but also representative of the entire tumour, and thus can be used for predictive mutation screening.

Acknowledgement: The authors would like to thank Gareth Cross for enabling the process of NGS data generation and analyses.

Compliance with Ethical Standards section

This work was funded by Universities of Nottingham (for MI) and Leeds (for SDR). All the authors declare that they have no conflict of interests in publishing this manuscript. Access to tissues and ethics approval were granted by Nottingham Health Sciences Biobank, which has approval as an IRB from North West—Greater Manchester Central Research Ethics Committee (REC reference: 15/NW/0685)..

References

- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015;136: E359-E386. doi:10.1002/ijc.29210
- Cancer Research UK (<u>http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/</u>). Accessed on 20/6/2018.
- 3. LeBlanc VG, Marra MA. Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us? Farah CS, Cho WC, eds. *Cancers*, 2015; 7(3):1925-1958. doi:10.3390/cancers7030869.
- Li J, Wang T, Zhang X, Yang X. The Contribution of Next Generation Sequencing Technologies to Epigenome Research of Stem Cell and Tumorigenesis. Human Genet Embryol, 2011; S2:001. doi: 10.4172/2161-0436.S2-001
- Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy incolorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Molecular Oncology, 2017;11(2):208-19.
- Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Mol Diagn. 2017;19(2):187-225..
- Santos MD, Silva C, Rocha A, Nogueira C, Castro-Poças F, Araujo A, et al. Predictive clinical model of tumor response after chemoradiation in rectal cancer. Oncotarget, 2017;8(35):58133-51.
- Lim SH, Chua W, Henderson C, Ng W, Shin JS, Chantrill L, et al. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Critical Reviews in Oncology / Hematology. 2015;96(1):67-80.
- 9. FoxTROT Collaboration Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. The Lancet Oncology, 2012;13(11):1152-60.

- Jakobsen A, Andersen F, Fischer A, Jensen LH, Jørgensen JCR, Larsen O, et al. Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. Acta Oncologica, 2015;54(10):1747-53.
- 11. Fadhil W, Ibrahem S, Seth R, AbuAli G, Ragunath K, Kaye P, et al. The utility of diagnostic biopsy specimens for predictive molecular testing in colorectal cancer. Histopathology, 2012;61(6):1117-24.
- 12. Greaves M, Maley CC. Clonal evolution in cancer. Nature, 2012. 481(7381):306-313.
- 13. Fadhil W, Ibrahem S, Seth R, Ilyas M. Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue. Journal of Clinical Pathology, 2010;63(2):134-140.
- 14. Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M. Concomitant mutations and splice variants in *KRAS* and *BRAF* demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. Gut, 2009;58(9):1234-1241.
- 15. Quick calcs (www.graphpad.com/quickcalcs/kappa2/)
- 16. Kappa (www.vassarstats.net/kappa.html)
- 17. Nurwidya F, Takahashi F, Takahashi K. Gefitinib in the treatment of non-small cell lung cancer with activating epidermal growth factor receptor mutation. Journal of Natural Science, Biology, and Medicine, 2016;7(2):119-123. doi:10.4103/0976-9668.184695.
- Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert review of anticancer therapy, 2011;11(2):263-75.
- 19. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World Journal of Gastroenterology, 2016;22(19):4619-25.
- 20. Bokemeyer C, Cutsem EV, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer, 2012;48(10):1466-75.

- 21. Krol LC, 't Hart NA, Methorst N, Knol AJ, Prinsen C, Boers JE. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma. European Journal of Cancer, 2012;48(7):1108-15.
- 22. Ku BM, Heo MH, Kim J-H, Cho BC, Cho EK, Min YJ, et al. Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). Journal of Pathology and Translational Medicine, 2018;52(3):148-56.
- 23. Zheng G, Tsai H, Tseng L-H, Gocke CD, Eshleman JR, Netto G, Lin M-T. Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. Am J Clin Pathol, 2016;145:696-702.
- 24. Illei PB, Belchis D, Tseng L-H, Nguyen D, De Marchi F, Haley L, et al. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget, 2017;8(57):96684-96.
- 25. DiBardino D, Rawson D, Saqi A, Heymann J, Pagan C, Bulman W. Nextgeneration sequencing of non-small cell lung cancer using a customized, targeted sequencing panel: Emphasis on small biopsy and cytology. CytoJournal, 2017;14(1):7. Available from: http://www.cytojournal.com/text.asp?2017/14/1/7/202602
- 26. Catalogue of Somatic Mutation in Cancer at https://cancer.sanger.ac.uk/. Accessed on 20/6/2018.
- 27. The Cancer Genome Atlas at https://cancergenome.nih.gov/. Accessed on 20/6/2018.
- 28. Viera AJ, Garrett JM. Understanding inter-observer agreement: The kappa statistic. Family Medicine, 2005;37(5):360-363.
- 29. Tejpar S, Bertagnolli M, Bosman F, Lenz H-J, Garraway L, Waldman F, Warren R, et al. Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. The Oncologist, 2010; 15 (4): 390-404.
- 30. Dienstmann R, Elez E, Argiles G, et al. Analysis of mutant allele fractions in driver genes in colorectal cancer biological and clinical insights. Molecular Oncology, 2017;11(9):1263-1272. doi:10.1002/1878-0261.12099.

- 31. Shen S, Wei Y, Zhang R, et al. Mutant-allele fraction heterogeneity is associated with non-small cell lung cancer patient survival. Oncology Letters, 2018;15(1):795-802. doi:10.3892/ol.2017.7428.
- 32. Ono A, Kenmotsu H, Watanabe M, Serizawa M, Mori K, Imai H, et al. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation. Annals of Oncology, 2014; 25(10):1948–1953. https://doi.org/10.1093/annonc/mdu251
- 33. Doma V, Papp O, Rásó E, Barbai T, Reiniger L, Vízkeleti L, Timar J. Alteration of mutant allele frequency in visceral metastases of melanoma. Journal of Clinical Oncology, 2018 36:15_suppl, e21528-e21528
- 34. Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases. Clinical Cancer Research, 2010;16(3):790-799.
- 35. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose Deprivation Contributes to the Development of *KRAS* Pathway Mutations in Tumor Cells. Science, 2009;325(5947):1555-1559.

FIGURE LEGENDS


Figure 1: Scatter plots showing the extent of agreement between Rx and Bx in the somatic mutation profile (A), allelic imbalance (AI) status (B) and mutant allele frequency (MAF) ratios (C). All the detected mutations, regardless of the MAF were included in the data that produced the somatic mutation profile and MAF ratios plots. The scatter plots show 'almost perfect' concordance in the somatic mutation profile to 'very good' and 'good' agreements in the AI status and MAF ratios, respectively.

Online Resource Figure 1: Validation of NGS-detected mutations by HRM analysis. Difference plots obtained for (A) *TP53* and (B) *KRAS*, by HRM analysis. The samples shown were identified by NGS as harbouring mutations and were confirmed by HRM analysis.

Online Resource Figure 2: HRM Analysis Difference plots showing enrichment of mutant allele by COLD-PCR. (A) A *PIK3CA* (c.331_333deIAAG) mutation was detected by NGS in this sample. Plot 1 represents PCR products obtained by QMC-PCR, whilst plot 2 denotes PCR products obtained by COLD-PCR. (B) A *SMAD4* (c.1082G>A) mutation detected by NGS. Plot 1 is PCR products obtained by QMC-PCR, whereas plot 2 is PCR products obtained by COLD-PCR. * denotes baseline normal DNA.

Online Resource Figure 3: A grid chart showing the agreement status between Bx and Rx using the 'mutation-present-or-absent' test. The coloured boxes denote presence of mutations, whilst the white boxes denote absence of mutations. The coloured boxes without numbers denote that there is only one mutation type between Rx/Bx pair; the numbers in some of the boxes denote the number of mutations for each gene found in the sample pair, whilst the * denotes that the matched Bx lacked the mutation that was found in the Rx. C=concordance, D=discordance.

Figure



*

Click here to access/download;Table;Revised List of Tables_Bx.vs.Rx_MDT.doc **±**

Sample No. Rx&Bx1	(
Rx&Bx1	Gene	Mutation	Amino acid changes	Rx-MAF (%)	Bx-MAF (%)	Rx-MAF ratios	Bx-MAF ratios	Agreement
	APC	c.3997delA	Frameshift	8.96	3.94	1	-	
	APC	c.4216C>T	Q>*	11.94	4.07	1.332589286	1.032994924	
	NRAS	c.35G>A	G>D	20.56	8.12	2.294642857	2.060913706	
	TP53	c.273G>A	W>*	28.68	4.79	3.200892857	1.215736041	υ
Rx&Bx2	APC	c.4216C>T	Q>*	21.99	12.96	1	1	
	KRAS	c.34G>T	G>C	33.5	22.45	1.523419736	1.732253086	U
Rx&Bx3	APC	c.4382_4383delAA		30.1	29.65	1	1	
	KRAS	c.35G>A	G>D	61.15	61.25	2.031561462	2.065767285	
	TP53	c.428T>A	V>E	50.79	49.97	1.687375415	1.685328836	
	FBXW7	c.1394G>A	R>H	32.07	30.91	1.065448505	1.042495784	
	SMAD4	c.1609G>T	D>Y	52.87	54.63	1.756478405	1.842495784	0
Rx&Bx4	APC	c.4375_4376insC	Frameshift	12.91	12.09	1	1	
	KRAS	c.35G>T	G>V	35.48	33.59	2.748257165	2.778329198	U
	TP53	402_403deITT	Frameshift	45.2	45.68	3.50116189	3.778329198	υ
Rx&Bx5	TP53	c.994-2A>C	Splice variant	31.11	35.74	1	1	
Rx&Bx6	APC	c.4326delT	Frameshift	13.39	6.02	1	1	
	KRAS	c.35G>T	G>V	24.49	11.85	1.828976848	1.968438538	υ
	PIK3CA	c.1633G>A	E>k	12.54	4.79	0.936519791	0.795681063	υ
Rx&Bx7	APC	c.4732deIT	Frameshift	11.66	9.56	1	1	
	KRAS	c.436G>A	A>T	11.83	9.45	1.01457976	0.988493724	U

Table 1: Concordance by total mutant allele frequency (MAF) ratios

		υ	٩	υ		٥		υ	U	U	υ		υ	υ		U	υ	υ		υ	υ	٥		U	υ
	1	1.069081154	1.350771294	0.254862508	1.16498994	0	1	1.098026316	1.115789474	1.1	1.184868421	1	0.894468705	0.300946143	1	0.762636274	0.690287413	0.689048563	1	0.954356846	0.782157676	0	1	0.8791894	0.915042868
	1	1.175298805	0.539043825	0.155378486	0.407569721	0.134661355	1	1.204339964	1.235081374	1.256781193	1.048824593	1	0.939317954	0.332998997	1	0.584356526	0.567985448	0.63165075	1	0.727093596	0.649261084	0.300492611	1	0.817365269	0.905688623
,	14.91	15.94	20.14	3.8	17.37	States and a second	15.2	16.69	16.96	16.72	18.01	27.48	24.58	8.27	40.36	30.78	27.86	27.81	4.82	4.6	3.77		12.83	11.28	11.74
1	25.1	29.5	13.53	3.9	10.23	3.38	5.53	6.66	6.83	6.95	5.8	19.94	18.73	6.64	21.99	12.85	12.49	13.89	10.15	7.38	6.59	3.05	6.68	5.46	6.05
	Frameshift	G>V	R>H	R>*	Frameshift	R>H	E>*	Frameshift	A>V	G>D	D>A	Q>*	G>C	P>H	G>D	R>C	R>*	R>C	G>V	Frameshift	Frameshift	S>F	Frameshift	Q>L	H>L
	c.4660_4661insA	c.35G>T	c.524G>A	c.886C>T	c.331_333delAAG	c.2543C>T	c.3925G>T	c.3940_3941deIAG	c.3946C>T	c.38G>A	c.623A>G	c.4216C>T	c.34G>T	c.290C>A	c.35G>A	c.523C>T	c.1177C>T	c.1513C>T	c.35G>T	c.186_193delAGCTC	c.247_249invTTT	c.2531G>A	c.4385_4386delAG	c.1637A>T	c.1136A>T
-	APC	KRAS	TP53	TP53	PIK3CA	GNAS	APC	APC	APC	KRAS	TP53	APC	KRAS	PIK3CA	KRAS	TP53	FBXW7		KRAS	TP53	PIK3CA	GNAS	APC	PIK3CA	FBXW7
Rx&Bx8	Rx&Bx9						Rx&Bx10					Rx&Bx11			Rx&Bx12				Rx&Bx13				Rx&Bx14		

J		,			U		U	υ	U	U	υ			U	U		υ		υ		0		υ	υ	U	υ
1.615744349	0.265003897			1	1.708699348		0.548907563	1.410420168	0.517647059	0.13210084	1.28			1.031586022	1.89516129	1.484543011	1.20766129	1	1.776607337			1	0.990208078	1.116891065	3.195838433	1.00122399
1.511976048	0.818862275			1	1.63506028	1	0.550164474	1.423930921	0.535773026	0.141447368	1.812911184		1	1.024006984	1.113705805	0.366870362	1.058489742	1	1.463179279	1	5.810559006	1	0.993405276		3.097122302	1.061151079
20.73	3.4		T	35.29	60.3	29.75	16.33	41.96	15.4	3.93	38.08		14.88	15.35	28.2	22.09	17.97	27.53	48.91	ACTIVITY OF	22.23	16.34	16.18	18.25	52.22	16.36
10.1	5.47			30.69	50.18	24.32	13.38	34.63	13.03	3.44	44.09		45.82	46.92	51.03	16.81	48.5	19.69	28.81	3.22	18.71	16.68	16.57	16.97	51.66	17.7
Splice variant	R>H			D>N	R>C	LQ>L*	G>D	R>C	K>E	E>K	R>W		Frameshift	S>R	A>T	G>R	R>C	V>E	C>F	P>L	R>H	Frameshift	Frameshift	G>V	K>E	E>K
c.801+1G>A	c.1082G>A		F	c.1780G>A	c.817C>T	c.4011_4012del	c.38G>A	c.817C>T	c.874A>G	c.1633G>A	c.2065C>T		c.4529delG	c.4530C>A	c.436G>A	c.316G>C	c.1513C>T	c.1799T>A	c.404G>T	c.23C>T	c.524G>A	c.4263_4264insA	c.4264_4271del	c.35G>T	c.874A>G	c.1633G>A
PTEN	SMAD4		1	BRAF	TP53	APC	KRAS	TP53	TP53	PIK3CA	FBXW7	10	APC	APC	KRAS	PIK3CA	FBXW7	BRAF	TP53	TP53	TP53	APC	APC	KRAS	TP53	PIK3CA
			Rx&Bx15	Rx&Bx16		Rx&Bx17							Rx&Bx18					Rx&Bx19		Rx&Bx20		Rx&Bx21				

			Γ	Γ										
U	U				U	U	U	U	U		U			
0.755813953	0.427172583			Ţ	2.034511435	1.733471933	1.986694387		0.781704782	1	0.381443299			
0.655275779 0.755813953	0.596522782			1	2.031548056	1.862068966	3.744680851	1.008804109	0.771093177	1	0.206017005			
12.35	6.98	30.03		24.05	48.93	41.69	47.78	26.56	18.8	4.85	1.85	(*	36.21	lant
10.93	9.95	21.52		13.63	27.69	25.38	51.04	13.75	10.51	15.29	3.15		22.2	*C= concordant, D=discordant
L>W	G>D	R>H		A>V	E>*	G>D	P>S	Frameshift	R>C	R>W	Frameshift		Y>C	*C= concorc
c.1091T>G	c.1094G>A	c.524G>A		c.2663C>T	c.4222G>T	c.35G>A	c.229C>T	c.325_327delGAA	c.1393C>T	c.844C>T	c.795delA		c.659A>G	
SMAD4		TP53		APC	APC	KRAS	TP53	PIK3CA	FBXW7	TP53	PTEN		TP53	
		Rx&Bx22		Rx&Bx 23						Rx&Bx24			Rx&Bx25	

Table 2: Allelic imbalance (Al) status of Rx and Bx


Sample pair No.	Informative SNP Loci	Rx	Bx	Al status pair	Agreement per SNP locus
-	rs2228230	45.29	48.16	NAI/NAI	o
	rs1050171	50.64	50.39	NAI/NAI	U
2	rs3733542	49.67	47.62	NAI/NAI	C
	rs41115	48.31	50.48	NAI/NAI	o
	rs1050171	71.56	61.82	LWA/LWA	U
3	rs41115	48.24	50.73	NAI/NAI	O
	rs1050171	50.62	48.36	NAI/NAI	O
	rs2023748	46.73	45.25	NAI/NAI	o
	rs41737	52.49	52.3	NAI/NAI	υ
	rs1137282	26.2	24.76	LPA/LPA	o
4	rs1050171	56.24	49.35	NAI/NAI	U
	rs2023748	40.86	38.53	LPA/LPA	o
	rs41737	44.63	40.59	NAI/LPA	D
5	rs2228230	34.51	43.18	LPA/LPA	U
	rs1042522	25.62	44.24	LPA/NAI	٥
9	rs41115	37.2	31.16	LPA/LPA	U
7	rs2228230	42.42	43.24	LPA/LPA	o
	rs41115	62.91	62	LWA/LWA	U
	rs2229066, rs17290559	48.83	48.74	NAI/NAI	U
	rs2023748	44.9	47.1	NAI/NAI	0

rs41737 50	rs1137282 40		rs41115 64		rs1042522 53	rs2228230 34	rs3733542 50	rs41115 50	rs2023748 56	rs41737 58	rs1042522 75	rs1050171 63	rs41737 42	rs1042522 40	rs41737 57	rs2228230 47		rs1050171 53	rs41737 46	rs3733542 48	rs41115 54
50.31 48.49		63.53 64.22	64.73 63.53	47.31 48.64	53.95 58.39	34.4 33.38	50.4 49.45	50.37 47.18	56.85 55.89	58.6 59.13	75.14 75.12	63.04 65.31	42.69 38.51	40.24 33.67	57.12 49.75	47.47 46.37	47.75 47.38	53.44 42.62	46.97 48.12	48.36 48.86	54.99 52.48
NAI/NAI	LPA/LPA	LWA/LWA	LWA/LWA	NAI/NAI	NAI/LWA	LPA/LPA	NAI/NAI	NAI/NAI	LWA/NAI	LWA/LWA	LWA/LWA	LWA/LWA	LPA/LPA	LPA/LPA	LWA/NAI	NAI/NAI	NAI/NAI	NAI/LPA	NAI/NAI	NAI/NAI	NAI/NAI
υ	U	υ	U	0	٥	O	O	U		O	U	O	O	U	D	υ	U	٥	ပ	υ	O

 rs2229066, rs17290559	41.66	41.61	LPA/LPA	υ
rs2023748	49.58	49.1	NAI/NAI	0
rs2228230	48.77	47.72	NAI/NAI	O
rs41115	48.42	48.31	NAI/NAI	υ
rs2228230	48.03	49.54	NAI/NAI	o
rs3733542	50.1	48.41	NAI/NAI	υ
rs41115	53.2	57.51	NAI/LWA	٥
rs1050171	48.24	54.96	NAI/NAI	v
rs2228230	48.78	49.11	NAI/NAI	O
rs3733542	48.9	50.2	NAI/NAI	ပ
rs41115	38.28	35.64	LPA/LPA	ပ
rs1050171	52.07	48.21	NAI/NAI	ပ
rs1137282	53.27	53.53	NAI/NAI	ပ
rs1042522	51.12	53.7	NAI/NAI	υ
rs41115	49.12	51.38	NAI/NAI	U
rs3733542	50.07	49.69	NAI/NAI	o
rs41115	53.99	50.71	NAI/NAI	ပ
rs1050171	35.47	41.93	LPA/LPA	U
rs2023748	41.4	46.13	LPA/NAI	٥
rs1050171	49.13	47.1	NAI/NAI	o
rs35775721	48.11	44.83	NAI/NAI	U
rs33917957	46.52	42.93	NAI/LPA	٥

rs56391007	53.05	50.68	NAI/NAI	ပ
 NM_001127500.1	49.54	49.94	NAI/NAI	O
NM_001127500.1	45.63	47.9	NAI/NAI	O
NM_001127500.1	53.3	51.89	NAI/NAI	O
NM_033360.2	48.23	46.66	NAI/NAI	O
rs1042522	53.09	54.2	NAI/NAI	U
rs55789615	50.07	50.03	NAI/NAI	O
rs1050171	51.67	49.47	NAI/NAI	U
rs3733542	49.49	48.09	NAI/NAI	O
rs41115	36.03	24.57	LPA/LPA	O
rs1050171	50.49	50.7	NAI/NAI	0
rs2023748	46.86	49.58	NAI/NAI	O
rs41737	48.55	53.15	NAI/NAI	υ
rs41115	48.3	49.92	NAI/NAI	O
rs1050171	48.7	48.05	NAI/NAI	0
rs1137282	53.07	53.17	NAI/NAI	O

*C= concordant, D=discordant, I=indeterminate, NAI=nil allelic imbalance, LPA= allelic imbalance with loss of polymorphic allele, LVVA= allelic imbalance with loss of wild-type allele



-98

- 47 - 60

ة Temperature

- 64 60

100


-6-

8

89 Temperature

- 30) - 60)

in the second se



Page	0
------	---

SAMPLU NU	APC			FBXW7			GNAS			PIK3CA		And a second	PTEN		and the second second second second	KRAS			BRAF		and the second se	SMAD4			TP53			NRAS			CANAGE F ANY
-	1	N	ž			U			U			U			U			U			U			U			U			U	t
4			0	+	1	U	-	-	U	-	1	U	-		4			U		-	U V	-	1	J		E	U	「「		U	
54		-	U	-		J			U	-	-	V	_		U			U	_	-+	U			U	3		<u>ں</u>		_	U	ļ.
7		100	0		-	Q		_	ų		-+	ų	-		U		-	U	-	-	J			U	1		v			U	t
^		-	U			v			U		-	U		+	U			u		-	U		-+-	U	A.	and the second	U			U	ł
5			S			J			U			U			U			U			U			U			U U			U	And in case of the local division of the loc
~			J			J		r i conti	U	-interested		υ			u			U			J			U			U U			υ	And in case of the local division of the loc
20			v			Ų			U			v			U		-	J			ų		1	J			J			Ų	and in succession of
e 1			J			J	•		0			U			U			υ			ų			U			U			Ų	Conceptual Street, or other
2		m	R			J			U			U			U			J			J			J			S			J	Name of Amounts
=			υ			υ		-	υ			u			υ			U			J			U	_		o			U	And the Party of Concession, Name
17			U		- 4	20			U			U			U			J			J		-	υ	and and a second second	1	U			υ	「「「「「」」」」
<u> </u>			U			U			٥	-		U			U			J		anar	U			U.		and the second	U			U	「「「「「」」」
2			0			U			U			U			U			U			U			U		-	U U			U	「「「「「「「」」」」
2			S			v			U			U	100		U		_	V			U			U			U			U	The local division in which the local division is not the local division of the local division is not the local division of the loca
9	-	_	Q	_	_	U			U			U			U	_	_	U			U		-	U	1		U			J	and
1			Y			Ų			ų			ų			Ų			V			ų		-	U		2	20			Ų	Contraction of the local division of the loc
8			2			U			U			U			U			U			U		_	U			U D		_	U	- and the second
19		est.	2C C			Ų		_	U			U			U			U			U			U	ALC: N		U			U	- Annual
8			c			U			U		-	U			U			U			U			U	and the second s	Charles Bar	۵ ۲			0	Contraction of the local division of the loc
21		-	20			0			U		-	J			U			v			C		-	20	Contraction of the local division of the loc	and a state	0			U	Contraction of the local division of the loc
2		-	0			С С		-	U		_	U			U			Ų			J			0		にに	v			U	
1		~	20			U			U			U			U			0			J		_	U		STATES OF	0	-		U	
1	Real Property		U			U		-	U	-	_	U			J			J	-		V			U			U I	-		U	-
52	_		C			U		_	U			U	-		U		_	Q			O			U	and the second		0			U	Contraction of the local distribution of the
	Ϋ́Β	Rx		8×	RX	motors	B×	R× X		Bx	RX		Bx	Ŗ	-	Ц,	Rx		BX	æ	tainma	Ě	Å	Landgeric	BX	R×	attender hal	8×	RX		on Reservence

Figure

Click here to access/download;Table;REVISED ONLINE RESOURCE TABLES_Bx.vs.Rx_MDT.doc

ON-LINE RESOURCE TABLES

Table 1: Clinicopathological char	acteristics of cases
Variable	Number %
Median age range	76 (48-87)
Gender	
Male	10 (40%)
Female	10 (40%)
Unknown	5 (20%)
Primary site	
Colon	16 (64%)
Rectum	5 (20%)
Unknown	4 (16%)
Primary T stage site	
T1	2(8%)
T2	4 (16%)
Т3	13(52%)
Τ4	1(4%)
Unknown	5 (20%)
Primary N stage site	
NO	14(56%)
N1	3(12%)
N2	3(12%)
Unknown	5 (20%)
Tumour grade	
Moderately differentiated	16(64%)
Poorly differentiated	1 (4%)
Other	2 (8%) 6 (24%)
Unknown	

Table

Table 2: Details and frequency of all variants detected in both biopsy and resection specimens.

						Resection			Rinney	
Case No.	Gene	Mutation	Codon	Exon	Dood	Alt road	Alt wariant	Deed	Altered	A 14
					depth	depth	Freq %	depth	Ait read depth	Ait variant Freq %
Rx&Bx1	APC	c.3997delA	1333	15	12904	1156	8.96	32117	1267	3.94
	APC	c.4216C>T	1406	15	25233	3014	11.94	25829	1050	4.07
	NRAS	c.35G>A	12	2	13572	2791	20.56	17257	1401	8.12
	TP53	c.273G>A	91	4	4784	1372	28.68	11000	527	4.79
Rx&Bx2	APC	c.4216C>T	1127	15	11971	2632	21.99	14951	1938	12.96
	KRAS	c.34G>T	12	2	10275	3442	33.5	12183	2735	22.45
Rx&Bx3	APC	c.4382_4383del	1461	15	6409	1929	30.1	10671	3164	29.65
	KRAS	c.35G>A	12	2	17219	10529	61.15	13894	8510	61.25
	TP53	c.428T>A	143	5	6243	3171	50.79	7578	3787	49.97
	FBXW7	c.1394G>A	465	8	27409	8791	32.07	29735	9191	30.91
	SMAD4	c.1609G>T	537	11	21170	11192	52.87	23362	12762	54.63
Rx&Bx4	APC	c.4375_4376ins	1459	15	17179	2218	12.91	13800	1669	12.09
	KRAS	c.35G>T	12	2	7925	2812	35.48	6180	2076	33.59
	TP53	402_403delTT	332	10	9646	4360	45.2	12112	5533	45.68
Rx&Bx5	TP53	c.994-2A>C	332	10	1366	425	31.11	3856	1378	35.74
-										
Rx&Bx6	APC	c.4326delT	1442	15	26131	3500	13.39	11468	690	6.02
	KRAS	c.35G>T	12	2	11570	2834	24.49	6137	727	11.85
	PIK3CA	c.1633G>A	545	6	41341	5185	12.54	14994	841	4.79
Rx&Bx7	APC	c.4732delT	1578	15	11433	1333	11.66	9729	930	9.56
	KRAS	c.436G>A	146	4	38504	4554	11.83	31484	2974	9.45

	14.91	15.94	20.14	3.8	17.37		15.2	16.69	16.96	16.72	18.01	27.48	24.58	8.27		40.36	30.78	27.86	27.81		4.82	4.6	3.77		12.83	11.28	11.74
1	2791	1019	1547	81	2693		4277	4700	4818	1030	961	4529	1442	1193	and a second sec	2287	1742	2195	3140		347	1123	452		758	2035	1297
	18723	6392	7680	2104	15502		28474	28154	28403	6162	5336	16480	5866	14432		5667	5659	7879	11290		7205	24144	11986		5907	18036	11048
1	25.1	29.5	13.53	3.9	10.23	3.38	5.53	6.66	6.83	6.95	5.8	19.94	18.73	6.64		21.99	12.85	12.49	13.89		10.15	7.38	6.59	3.05	6.68	5.46	6.05
1	8978	2928	412	75	3184	566	1616	1938	1995	548	386	6371	2044	1223		2044	2008	2346	2062		889	1937	567	524	575	1611	708
1	35765	9924	3046	1902	31127	16759	29226	29086	29202	7884	6652	31948	10915	18426		9296	15627	14850	18781		8756	26264	8608	17158	8603	29501	11711
1	15	2	5	9	٢	8	15	15	16	2	9	15	2	-		2	5	6	11		2	4	1	8	15	6	7
	1554	12	175	196	111	201	1309	1314	1316	13	208	1406	12	97		12	175	393	505	10	12	79-81	83	205	1462	546	379
1	c.4660_4661ins	c.35G>T	c.524G>A	c.886C>T	c.331_333delAA	c.2543C>T	c.3925G>T	c.3940_3941del	c.3946C>T	c.38G>A	c.623A>G	c.4216C>T	c.34G>T	c.290C>A		c.35G>A	c.523C>T	c.1177C>T	c.1513C>T		c.35G>T	c.186_193delA	c.247_249invTT	c.2531G>A	c.4385_4386del	c.1637A>T	c.1136A>T
	APC	KRAS	TP53		PIK3CA	GNAS	APC			KRAS	TP53	APC	KRAS	PIK3CA		KRAS	TP53	FBXW7			KRAS	TP53	PIK3CA	GNAS	APC	PIK3CA	FBXW7
Rx&Bx8	Rx&Bx9						Rx&Bx10					Rx&Bx11				Rx&Bx12					Rx&Bx13				Rx&Bx14		

20.73	3.4	•	35.29	60.3	29.75	16.33	41.96	15.4	3.93	38.08		14.88	15.35	28.2	22.09	17.97	27.53	48.91		22.23	16.34	16.18	18.25	52.22	16.36
1609	293		7588	2354	3489	1470	3036	365	843	2409		3095	3144	8980	4402	1955	6644	4088	and the second second	2382	2303	2278	862	2536	2421
7763	8609		21500	3904	11729	0006	7236	5621	21438	6326		20798	20477	31842	19929	10881	24135	8358		10716	16064	16064	4723	4856	14794
10.1	5.47		30.69	50.18	24.32	13.38	34.63	13.03	3.44	44.09	A REAL PROPERTY AND A REAL	45.82	46.92	51.03	16.81	48.5	19.69	28.81	3.22	18.71	16.68	16.57	16.97	51.66	17.7
1308	746	,	7497	3083	5044	813	2345	267	184	3773		6772	6873	22746	3781	9603	6958	1836	164	2946	5301	5267	1736	2905	6285
12950	13633		24432	6144	20739	6077	6772	3481	14717	8557		14781	14647	44577	22486	19798	35332	6373	5086	15744	31777	31777	10231	5623	35510
2	6	1	15	8	15	2	8	80	6	11		15	15	4	+	6	15	5	2	5	15	15	2	80	6
*	361	1	594	273	1437-	13	273	292	545	689		1510	1510	146	106	505	600	135	8	175	1421	1422-	12	292	545
c.801+1G>A	c.1082G>A		c.1780G>A	c.817C>T	c.4011_4012del	c.38G>A	c.817C>T	c.874A>G	c.1633G>A	c.2065C>T		c.4529delG	c.4530C>A	c.436G>A	c.316G>C	c.1513C>T	c.1799T>A	c.404G>T	c.23C>T	c.524G>A	c.4263_4264ins	c.4264_4271del	c.35G>T	c.874A>G	c.1633G>A
PTEN	SMAD4		BRAF	TP53	APC	KRAS	TP53		PIK3CA	FBXW7		APC		KRAS	PIK3CA	FBXW7	BRAF	TP53	TP53	TP53	APC	APC	KRAS	TP53	PIK3CA
		Rx&Bx15	Rx&Bx16		Rx&Bx17							Rx&Bx18					Rx&Bx19		Rx&Bx20		Rx&Bx21				

12.35	6.98	30.03	24.05	48.93	41.69	47.78	26.56	18.8		4.85	7.91	36.21
				4					_			
751	416	4553	3810	6999	3261	026	4469	3383		215	359	2132
6080	5963	15164	15845	13631	7822	2030	16829	17997		4430	4541	5888
10.93	9.95	21.52	13.63	27.69	25.38	51.04	13.75	10.51		15.29	14.5	22.2
1650	1477	1818	2768	5688	1915	737	3506	2956		548	569	750
15094	14850	8447	20303	20542	7544	1444	25505	28121		3584	3924	3379
6	ი	5	15	15	2	4	1	∞		8	7	7
364	365	175	888	1408	12	77	109	465		282	267	220
c.1091T>G	c.1094G>A	c.524G>A	c.2663C>T	c.4222G>T	c.35G>A	c.229C>T	c.325_327delG	c.1393C>T		c.844C>T	c.795delA	c.659A>G
SMAD4		TP53	APC		KRAS	TP53	PIK3CA	FBXW7		TP53	PTEN	TP53
		Rx&Bx22	Rx&Bx							Rx&Bx24		Rx&Bx25

			Rx	0				
		Positive	Negative	Measures				
	Positive	TP =	FP =	PPV =				
		78	0	100%				
Bx	Negative	FN =	TN =	NPV =				
		3	180	98.4%				
	Measures	Sensitivity= 96.3%	Specificity= 100%	Accuracy = 98.85%				

Table 3: Performance Indices for assays

Sensitivity= TP/(TP+FN); Specificity= TN/(TN+FP); PPV= TP/(TP+FP); NPV= TN/(TN+FN); FPR= FP/(FP+TN) = 1 - specificity; FNR= FN/(TP+FN) = 1 - sensitivity; FDR= FP/(TP+FP)

